Rheumatoid Arthritis Treatment on the Horizon as FDA Approves Erelzi
A new treatment option for patients with inflammatory joint disease is on the way. In August 2016, the U.S. Food and Drug Administration (FDA) approved Erelzi (etanercept-szzs). Erelzi is biosimilar to Enbrel (etanercept) and is approved to treat the same types of spinal inflammatory arthritis, such as rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing spondylitis.
Erelzi is administered via injection. It is considered biosimilar to the biologic medication Enbrel, though the drugs are not interchangeable. A biosimilar is a biological product that is very similar to an approved biologic, and has no major differences in terms of safety and effectiveness.
The FDA’s approval of Erelzi means more patients will have access to a quality treatment to help manage their joint pain and other symptoms of spinal inflammatory arthritis.
Though it achieved FDA approval, Erelzi is not yet available in the U.S. market. If you have spinal inflammatory arthritis, your doctor may recommend Erelzi as a treatment option once it becomes available.
To learn more about advanced medications that relieve symptoms of spinal inflammatory arthritis, read Biologic Drugs for Back Pain and Neck Pain.